¼Ò¾Æ ½Å°æ º£Ã¼Æ®º´¿¡¼ È¿°úÀûÀÎ Infliximab Ä¡·á »ç·Ê
Successful Treatment of Child Neuro-Behcet¡¯s Disease with Infliximab
´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö 2014³â 21±Ç 4È£ p.209 ~ p.213
ÇãÁö¾Ö(Hur Ji-Ae) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½º¾î¸°À̺´¿ø ¼Ò¾Æû¼Ò³â°úÇб³½Ç
±èµ¿¼ö(Kim Dong-Soo) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½º¾î¸°À̺´¿ø ¼Ò¾Æû¼Ò³â°úÇб³½Ç
±è±âȯ(Kim Ki-Hwan) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½º¾î¸°À̺´¿ø ¼Ò¾Æû¼Ò³â°úÇб³½Ç
Abstract
Behcet¡¯s disease is a systemic vasculitis, characterized by recurrent oral aphthous ulcers, recurrent genital ulcers, skin lesion, and ocular involvement. Monoclonal antibody to the tumor necrosis factor-¥á (TNF-¥á) is considered as a possible therapeutic approach to achieve clinical im-provement, preventing relapse in Behcet¡¯s disease re-fractory to conventional anti-inflammatory drugs or im-munosuppressive durgs. We report the use of infliximab, which is one of the TNF-¥á monoclonal antibodies, in a 17-year-old girl with Behcet¡¯s disease exhibiting severe mucocutaneous, ocular and neurological involvement re-fractory to standard treatment.
Å°¿öµå
Child, Neuro-Behcet disease, Infliximab
KMID :
0388220140210040209
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)